The influence of probiotic treatment on sulfasalazine metabolism in rat

References

• Ahnfelt NO, Modin R, Odell ML, Ohlson U. (1986). Determination of salicylazosulphapyridine, sulphapyridine and its metabolites in serum and urine. J Pharm Biomed Anal 4:261–269.
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Guthrie G, Johnston HH, Truelove SC, Williamson DH. (1983). Tissue and bacterial splitting of sulphasalazine. Clin Sci 64:349–354.
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Truelove SC. (1980). Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis. Gut 21:706–710.
   PubMedGoogle Scholar
• Azad Khan AK, Truelove SC, Aronson JK. (1982). The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol 13:523–528.
   PubMed Web of Science ®Google Scholar
• Bird HA. (1995). Sulphasalazine, sulphapyridine or 5-aminosalicylic acid–which is the active moiety in rheumatoid arthritis? Br J Rheumatol 34 Suppl 2:16–19.
   PubMedGoogle Scholar
• Chapman TM, Plosker GL, Figgitt DP. (2006). VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs 66:1371–1387.
   PubMed Web of Science ®Google Scholar
• Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z. (2007). N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol 21:155–158.
   PubMed Web of Science ®Google Scholar
• Chungi VS, Rekhi GS, Shargel L. (1989). A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids. J Pharm Sci 78:235–238.
   PubMed Web of Science ®Google Scholar
• Das KM, Chowdhury JR, Zapp B, Fara JW. (1979). Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology 77:280–284.
   PubMed Web of Science ®Google Scholar
• Das KM, Dubin R. (1976). Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1:406–425.
   PubMed Web of Science ®Google Scholar
• Das KM, Eastwood MA, McManus JP, Sircus W. (1973). Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289:491–495.
   PubMed Web of Science ®Google Scholar
• De Preter V, Raemen H, Cloetens L, Houben E, Rutgeerts P, Verbeke K. (2008). Effect of dietary intervention with different pre- and probiotics on intestinal bacterial enzyme activities. Eur J Clin Nutr 62:225–231.
   PubMed Web of Science ®Google Scholar
• Farr M, Bacon PA, Coppock J, Scott DL. (1987). Long term experience of salazopyrin EN in rheumatoid arthritis (RA). Scand J Rheumatol Suppl 64:37–47.
   PubMedGoogle Scholar
• Goldin B, Gorbach SL. (1977). Alterations in fecal microflora enzymes related to diet, age, Lactobacillus supplements, and dimethylhydrazine. Cancer 40:2421–2426.
   PubMed Web of Science ®Google Scholar
• Goldin BR, Gorbach SL. (2008). Clinical indications for probiotics: an overview. Clin Infect Dis 46 Suppl 2:S96–100; discussion S144.
   PubMedGoogle Scholar
• Goossens D, Jonkers D, Russel M, Stobberingh E, Van Den Bogaard A, StockbrUgger R. (2003). The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Aliment Pharmacol Ther 18:495–505.
   PubMed Web of Science ®Google Scholar
• Ilett KF, Tee LB, Reeves PT, Minchin RF. (1990). Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 46:67–93.
   PubMed Web of Science ®Google Scholar
• Jenks K, Stebbings S, Burton J, Schultz M, Herbison P, Highton J. (2010). Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol 37:2118–2125.
   PubMed Web of Science ®Google Scholar
• Kanerud L, Scheynius A, Nord CE, Hafström I. (1994). Effect of sulphasalazine on gastrointestinal microflora and on mucosal heat shock protein expression in patients with rheumatoid arthritis. Br J Rheumatol 33:1039–1048.
   PubMedGoogle Scholar
• Kato R, Yuasa H, Inoue K, Iwao T, Tanaka K, Ooi K, Hayashi Y. (2007). Effect of Lactobacillus casei on the absorption of nifedipine from rat small intestine. Drug Metab Pharmacokinet 22:96–102.
   PubMed Web of Science ®Google Scholar
• Klotz U. (1985). Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10:285–302.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Orlovich DA, Tagg JR, Fawcett JP. (2009). Detection and specific enumeration of multi-strain probiotics in the lumen contents and mucus layers of the rat intestine after oral administration. Probiotic & Antimicro Prot 1:113–120.
   PubMedGoogle Scholar
• Lee HJ, Waller RD, Stebbings S, Highton J, Orlovich DA, Schmierer D, Fawcett JP. (2010). The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study. Int J Rheum Dis 13:48–54.
   PubMed Web of Science ®Google Scholar
• Liang E, Proudfoot J, Yazdanian M. (2000). Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers. Pharm Res 17:1168–1174.
   PubMed Web of Science ®Google Scholar
• Macfarlane GT, Cummings JH. (1999). Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? BMJ 318:999–1003.
   PubMed Web of Science ®Google Scholar
• Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. (2001). Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121:580–591.
   PubMed Web of Science ®Google Scholar
• Mercer M, Brinich MA, Geller G, Harrison K, Highland J, James K, Marshall P, McCormick JB, Tilburt J, Achkar JP, Farrell RM, Sharp RR. (2012). How patients view probiotics: findings from a multicenter study of patients with inflammatory bowel disease and irritable bowel syndrome. J Clin Gastroenterol 46:138–144.
   PubMed Web of Science ®Google Scholar
• Mikov M, Lee HJ, Fawcett JP. (2006). The influence of probiotic treatment on sulfasalazine metabolism in rat gut contents. Asian J Pharmacokinet Pharmacodynam 6:337–342.
   Google Scholar
• Mitsuyama K, Sata M. (2008). Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opin Ther Targets 12:301–312.
   PubMed Web of Science ®Google Scholar
• Mountzouris KC, Kotzampassi K, Tsirtsikos P, Kapoutzis K, Fegeros K. (2009). Effects of Lactobacillus acidophilus on gut microflora metabolic biomarkers in fed and fasted rats. Clin Nutr 28:318–324.
   PubMedGoogle Scholar
• Ohland CL, Macnaughton WK. (2010). Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298:G807–G819.
   PubMed Web of Science ®Google Scholar
• Ouwehand AC, Lagström H, Suomalainen T, Salminen S. (2002). Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 46:159–162.
   PubMed Web of Science ®Google Scholar
• Pontier C, Pachot J, Botham R, Lenfant B, Arnaud P. (2001). HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J Pharm Sci 90:1608–1619.
   PubMed Web of Science ®Google Scholar
• Reid G. (2006). Safe and efficacious probiotics: what are they? Trends Microbiol 14:348–352.
   PubMed Web of Science ®Google Scholar
• Rowland IR, Mallett AK, Bearne CA, Farthing MJ. (1986). Enzyme activities of the hindgut microflora of laboratory animals and man. Xenobiotica 16:519–523.
   PubMed Web of Science ®Google Scholar
• Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. (2000). Bioanalytical method validation–a revisit with a decade of progress. Pharm Res 17:1551–1557.
   PubMedGoogle Scholar
• Tannock GW, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. (2000). Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 66:2578–2588.
   PubMed Web of Science ®Google Scholar
• Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC. (2004). Monostrain, multistrain and multispecies probiotics–A comparison of functionality and efficacy. Int J Food Microbiol 96:219–233.
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. (2004). Low dose balsalazide plus high-potency probiotic preparation is more effective then balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10:PI126–131.
   PubMed Web of Science ®Google Scholar
• Wingate D, Phillips SF, Lewis SJ, Malagelada JR, Speelman P, Steffen R, Tytgat GN. (2001). Guidelines for adults on self-medication for the treatment of acute diarrhoea. Aliment Pharmacol Ther 15:773–782.
   PubMed Web of Science ®Google Scholar
• Wise A, Mallett AK, Rowland IR. (1982). Dietary fibre, bacterial metabolism and toxicity of nitrate in the rat. Xenobiotica 12:111–118.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sasaki K, Kurosaki Y, Nakayama T, Kimura T. (1994). Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid. J Drug Target 2:123–131.
   PubMed Web of Science ®Google Scholar
• Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. (2002). Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 68:3401–3407.
   PubMed Web of Science ®Google Scholar